Introduction {#sec1}
============

The rapid spread of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) urges clinicians and researchers to analyze SARS-CoV-2 and to characterize the symptoms of COVID-19 \[[@bib1]\]. Previous studies reported the expression of ACE2, the entry receptor of SARS-CoV-2, on the human conjunctiva and cornea potentially resulting in conjunctivitis and keratitis \[[@bib2], [@bib3], [@bib4], [@bib5]\]. SARS-CoV-2 existed in COVID-19 patients\' tears and ocular involvement was present in 1-32% of hospitalized patients \[[@bib3],[@bib6]\]. Ocular involvement included chemosis, epiphora, secretion and conjunctival hyperemia \[[@bib6]\]. There are some studies regarding ocular manifestations in COVID-19 patients, but most of them evaluated hospitalized patients in China retrospectively \[[@bib3],[@bib5]\]. Therefore, the objectives of this study included to evaluate ocular symptoms in European non-hospitalized patients with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) and to investigate associations with the demographic data as well as nasal and general physical symptoms.

Methods {#sec2}
=======

All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration. Institutional Review Board approval was obtained. Inclusion criteria were COVID-19 confirmed by polymerase chain reaction (PCR) in a throat-swab and age over 18 years. On eight consecutive days, these patients were identified by the records of the University Hospital of Cologne, Germany and all of them were called by phone. Exclusion criteria were hospitalization at any time point caused by COVID-19. Patients were asked using a standardized three-section questionnaire. Section [1](#sec1){ref-type="sec"} requested demographic data, general symptoms including fever, cough, headache, and sore throat as well as dates of the positive PCR test and of the first symptoms associated with COVID-19. Nasal symptoms which might influence ocular symptoms potentially were evaluated for nasal congestion, sneezing, nasal itching, and rhinorrhea using a four-point scale (0--3), respectively \[[@bib7]\]. A score of 0 indicated no symptoms, 1 documented mild symptoms that were easily tolerated, 2 described awareness of symptoms which were bothersome but tolerable, and 3 matched severe symptoms that were hard to tolerate and interfered with daily activities or sleep.

Section 2 asked for ocular symptoms during COVID-19 including burning sensations, itching, watering, mucoid and purulent discharge, photophobia, foreign body sensation, conjunctival swelling, eye lid swelling, feeling of pressure, double images, metamorphopsia, redness, reduced visual acuity, and pain for the right and the left eye, respectively. Furthermore, the date of the beginning of each symptom was noted. Total Ocular Symptom Score (TOSS) was evaluated for two different time points: retrospectively prior to coronavirus infection and during COVID-19. TOSS included ocular itching, redness, epiphora, and eye swelling. Each symptom was graded analogous to nasal symptoms and TOSS was then calculated by adding the four scores to a total score between 0-12. Section 3 requested pre-existing eye conditions, topical ocular medication, and ophthalmologist\`s visits during COVID-19. All statistical analyses were performed with SPSS Version 26.0 for Mac. Shapiro-Wilk tests were performed to analyze normal distribution. To compare ocular symptom scores before infection and during COVID-19 Wilcoxon tests were performed. To investigate factors related to TOSS a general linear model including analysis of variance (ANOVA) was used with explanatory variables of gender, age, rhinorrhea, nasal itching, sneezing, nasal congestion, cough, headache, fever, and sore throat. The threshold for statistical significance was set at p\<0.05.

Results {#sec3}
=======

115 non-hospitalized patients with COVID-19 were called and 109 of them were achieved by phone. 108 agreed to participate, 1 declined. Of these 108 patients, 51 were males and 57 females with a mean age of 37.9 ± 13.7 years (range, 18 -- 87 years). Mean time since PCR confirmed COVID-19 was 6.8 ± 1.5 days (range, 3 -- 9 days), and mean time since first symptoms occurred was 13.2 ± 3.8 days (range, 6 -- 23 days). 82 of the 108 COVID-19 patients (75.9%) suffered from cough, 80 (74.1 %) from headache, 63 (58.3%) from sore throat, and 47 (43.5%) from fever.

Mean scores were 1.02 ± 1.13 (range, 0 - 3) for nasal congestion, 0.57 ± 0.74 (range, 0 - 3) for sneezing, 0.16 ± 0.39 (range, 0 -- 2) nasal itching, and 0.70 ± 0.85 (range, 0 - 3) for rhinorrhea.

75 out of the 108 COVID-19 patients (69.4 %) suffered from at least one ocular symptom during COVID-19. The most common symptoms included burning sensations in 36.1%, epiphora in 34.3%, and redness in 25.9%, compatible with conjunctivitis ([Table 1](#tbl1){ref-type="table"} ). These ocular symptoms occurred mostly in the first three days after any symptom of COVID-19 was noticed. All scores were significantly higher during COVID-19 than the scores prior to infection (p≤0.022, respectively; [Table 2](#tbl2){ref-type="table"} ). Prior to COVID-19, two patients had previously diagnosed dry eye disease and one patient ocular allergy while six patients used sometimes artificial tears if needed and one patient antihistamines. During COVID-19 only one patient bought artificial tears and no patient was seen by an ophthalmologist. None of the investigated explanatory variables including gender, age, rhinorrhea, nasal itching, sneezing, nasal congestion, cough, headache, fever, and sore throat was associated with TOSS during COVID-19 (ANOVA: p=0.559; p≥0.05, respectively).Table 1Ocular Symptoms of 108 European Non-Hospitalized Patients (216 Eyes) with COVID-19Table 1Ocular SymptomsRight and left eyes with Symptoms, *no. (%)*Patients with bilateral symptoms, *no. (%)*Duration of Occurrence since first Symptom was noted (days), *mean ± SD (range)*Burning sensations76 (35.2%)37 (34.3%)1.89 ± 3.26 (range, 0 - 13)Itching38 (17.6%)18 (16.7%)2.53 ± 3.72 (range, 0 - 13)Epiphora (Watering eyes)71 (32.9%)34 (31.5%)1.91 ± 3.59 (range, 0 - 13)Mucoid discharge18 (8.3%)9 (8.3%)0.78 ± 1.09 (range, 0 - 13)Purulent Discharge0 (0.0%)0 (0.0%)-Photophobia44 (20.4%)22 (20.4%)1.77 ± 3.41 (range, 0 - 13)Foreign body sensation15 (6.9%)7 (6.5%)2.25 ± 2.12 (range, 0 - 6)Conjunctival swelling16 (7.4%)8 (7.4%)1.14 ± 1.46 (range, 0 - 3)Eye lid Swelling30 (13.9%)15 (13.9%)2.00 ± 2.88 (range, 0 - 10)Feeling of pressure45 (20.8%)22 (20.4%)2.04 ± 2.40 (range, 0 - 7)Double images4 (1.9%)2 (1.9%)3.50 ± 2.12 (range, 2 - 5)Metamorphopsia0 (0.0%)0 (0.0%)-Redness54 (25.0%)26 (24.1%)2.07 ± 2.67 (range, 0 - 10)Reduced visual acuity19 (8.8%)9 (8.3%)3.10 ± 2.60 (range, 0 - 7)Pain22 (10.2%)11 (10.2%)2.09 ± 2.12 (range, 0 - 7)Table 2Graded Ocular Symptoms and Total Ocular Symptom Score of 108 European COVID-19 Non-Hospitalized Patients Before Versus During COVID-19 Infection.Table 2Graded Ocular SymptomsBefore COVID-19During COVID-19P valueOcular Itching, *mean ± SD (range)*0.05 ± 0.25 (range, 0 - 2)0.30 ± 0.67 (range, 0 - 3)p=0.001 None, *n (%)*104 (96.3%)88 (81.5%)- Mild, *n (%)*3 (2.8%)9 (8.3%)- Moderate, *n (%)*1 (0.9%)10 (9.3%)- Severe, *n (%)*0 (0.0%)1 (0.9%)-Ocular Redness, *mean ± SD (range)*0.06 ± 0.27 (range, 0 - 2)0.33 ± 0.64 (range, 0 - 3)p\<0.001 None, *no. (%)*103 (95.4%)80 (74.1%)- Mild, *no. (%)*4 (1.9%)22 (20.4%)- Moderate, *no. (%)*1 (0.9%)4 (3.7%)- Severe, *no. (%)*0 (0.0%)2 (1.9%)-Epiphora, *mean ± SD (range)*0.17 ± 0.42 (range, 0 - 2)0.45 ± 0.72 (range, 0 - 3)p\<0.001 None, *no. (%)*92 (85.2%)71 (65.7%)- Mild, *no. (%)*14 (13.0%)27 (25.0%)- Moderate, *no. (%)*2 (1.9%)8 (7.4%)- Severe, *no. (%)*0 (0.0%)2 (1.9%)-Eye Swelling, *mean ± SD (range)*0.06 ± 0.31 (range, 0- 2)0.19 ± 0.51 (range, 0 - 3)p=0.022 None, *no. (%)*103 (95.4%)93 (86.1%)- Mild, *no. (%)*3 (2.8%)11 (10.2%)- Moderate, *no. (%)*2 (1.9%)3 (2.8%)- Severe, *no. (%)*0 (0.0%)1 (0.9%)-**Total Ocular Symptom Score,***mean ± SD (range)*0.33 ± 1.04 (range, 0 - 8)1.27 ± 1.85 (range, 0 - 12)p\<0.001

Discussion {#sec4}
==========

This prospective study showed for the first time the high prevalence of burning sensation, redness, and watering in non-hospitalized European COVID-19 patients. The consecutively enrolled patients were much younger than in previous studies including mostly inpatients in China \[[@bib3],[@bib6]\]. Younger patients without any preexisting conditions have normally a mild course of disease and need therefore not be hospitalized. Approximately one-third of the outpatients in this study had epiphora or burning sensations, respectively, and one fourth reported ocular redness. Therefore, the incidence of conjunctivitis, especially in outpatients, seems to be highly underestimated. Ocular symptoms occurred mostly in the first three days of COVID-19, but were usually rather mild. However, in some rare cases moderate or severe courses including subconjunctival bleedings, keratitis, or even vitreous hemorrhages can occur \[[@bib8],[@bib9]\].

The reasons why patients had no ophthalmologist's visit despite a high incidence of symptoms, stay unclear. The mild disease, fear of infection, and/or the home quarantine order by the health authorities might be possible reasons.

Since ocular symptoms were not associated with nasal symptoms, cough, headache, fever, or sore throat, these concomitant COVID-19 symptoms seem to have no significant impact on the ocular symptoms*.* Therefore, SARS-CoV-2 might have a significant causative influence on these ocular symptoms resulting in a high priority to investigate this in further prospective studies comparing the clinical ocular involvement of outpatients and inpatients. Eventually, the presence of clinical ocular manifestations in patients with COVID-19 might be a negative predictor of outcome \[[@bib10]\].

Nevertheless, there are some limitations of this study. First, TOSS before infection was evaluated retrospectively and second, all ocular symptoms were not confirmed by clinical examinations but only reported subjectively by patients on average 13 days after the first symptom occurred, thus during or in some few cases shortly after COVID-19.

Since these complaints were not associated with nasal symptoms, there is a high priority to evaluate the causative factors by prospective studies including clinical examinations.
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